A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients With Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Antofagasta, Chile
- Research Site
-
Santiago, Chile
- Research Site
-
-
-
-
-
Bratislava, Slovakia
- Research Site
-
Liptovsky Mikulas, Slovakia
- Research Site
-
Michalovce Stranany, Slovakia
- Research Site
-
Rimavska Sobota, Slovakia
- Research Site
-
Svidnik, Slovakia
- Research Site
-
Trnava, Slovakia
- Research Site
-
-
-
-
-
Cape Town, South Africa
- Research Site
-
Johannesburg, South Africa
- Research Site
-
Tygervalley, South Africa
- Research Site
-
-
-
-
California
-
Chino, California, United States
- Research Site
-
Lond Beach, California, United States
- Research Site
-
San Diego, California, United States
- Research Site
-
Stanford, California, United States
- Research Site
-
-
Connecticut
-
New Heaven, Connecticut, United States
- Research Site
-
-
Florida
-
Ft. Lauderdale, Florida, United States
- Research Site
-
Gainsville, Florida, United States
- Research Site
-
Lake City, Florida, United States
- Research Site
-
Miami, Florida, United States
- Research Site
-
Orlando, Florida, United States
- Research Site
-
St Petersburg, Florida, United States
- Research Site
-
-
Georgia
-
Atlanta, Georgia, United States
- Research Site
-
Decatur, Georgia, United States
- Research Site
-
-
Illinois
-
Hoffman Estates, Illinois, United States
- Research Site
-
Joliet, Illinois, United States
- Research Site
-
Skokie, Illinois, United States
- Research Site
-
-
Louisiana
-
Lake Charles, Louisiana, United States
- Research Site
-
Shreveport, Louisiana, United States
- Research Site
-
-
Maryland
-
Baltimore, Maryland, United States
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States
- Research Site
-
-
Missouri
-
St. Louis, Missouri, United States
- Research Site
-
-
New Jersey
-
Willingboro, New Jersey, United States
- Research Site
-
-
New York
-
Mount Kisco, New York, United States
- Research Site
-
New York, New York, United States
- Research Site
-
Rochester, New York, United States
- Research Site
-
-
North Carolina
-
Winston-Salem, North Carolina, United States
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States
- Research Site
-
Dayton, Ohio, United States
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Research Site
-
-
Texas
-
Dallas, Texas, United States
- Research Site
-
Houston, Texas, United States
- Research Site
-
-
Washington
-
Bellevue, Washington, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated informed consent before initiation of any study-related procedures.
- Male or female patients aged 18 to 70 years, inclusive.
- The patient must have a clinical diagnosis of major depressive disorder with a lifetime history of inadequate response to at least 3 antidepressants.
- Women of child-bearing potential must have a negative serum pregnancy test and confirmed use of a highly effective form of birth control before enrollment for a minimum of 3 months before study start.
- Outpatient status at screening and randomization visits.
Exclusion Criteria:
- Patients with a history of diagnosed bipolar disorder or schizophrenia or schizoaffective disorder or currently exhibiting psychotic features associated with their depression; dementia or suspicion thereof.
- Patients who have had a suicide attempt within the last 6 months.
- Electroconvulsive therapy (ECT), vagal nerve stimulation (VNS) or transcranial magnetic stimulation (TMS) or previous treatment with ketamine infusion within the 6 months prior to screening, or any history of deep brain stimulation.
- Patients with any history of seizure disorder (except for febrile seizures in childhood).
- Pregnancy or lactation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
|
|
Experimental: 2
|
50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
|
|
Placebo Comparator: 3
|
0.9 sodium chloride [normal saline] solution for injection by iv infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Time Frame: Baseline to Week 6
|
A 10-item scale for the evaluation of depressive symptoms.
Each MADRS item is rated on a 0 to 6 scale.
The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
|
Baseline to Week 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline to Week 12 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Time Frame: Baseline to Week 12
|
A 10-item scale for the evaluation of depressive symptoms.
Each MADRS item is rated on a 0 to 6 scale.
The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
|
Baseline to Week 12
|
|
Percentage of Patients With Sustained Response From Week 6 to Week 12 (Defined as ≥50% Reduction From Baseline in the MADRS Total Score at Week 6 and Which is Maintained Through Week 12)
Time Frame: Week 6 to Week 12
|
The percentage of patients with with Sustained Response (defined as ≥50% reduction from baseline in the MADRS total score at Week 6 and which is maintained through Week 12) was calculated.
|
Week 6 to Week 12
|
|
Percentage of Patients Who Were Responders (Defined as a ≥50% Reduction From Baseline in MADRS Total Score) at Week 6
Time Frame: Baseline to Week 6
|
The percentage of patients who were Responders (defined as ≥50% reduction from baseline in MADRS total score) was calculated.
|
Baseline to Week 6
|
|
Percentage of Patients Who Were Responders (Defined as a ≥50% Reduction From Baseline in MADRS Total Score) at Week 12
Time Frame: Baseline to Week 12
|
The percentage of patients who were Responders (defined as ≥50% reduction from baseline in MADRS total score) was calculated.
|
Baseline to Week 12
|
|
Percentage of Patients Who Were Remitted (Defined as MADRS Total Score ≤10) at Week 6
Time Frame: Baseline to Week 6
|
The percentage of patients who were Remitted (defined as MADRS total score ≤10) was calculated.
|
Baseline to Week 6
|
|
Percentage of Patients Who Were Remitted (Defined as MADRS Total Score ≤10) at Week 12
Time Frame: Baseline to Week 12
|
The percentage of patients who were Remitted (defined as MADRS total score ≤10) was calculated.
|
Baseline to Week 12
|
|
Change From Baseline in Functional Impairment as Measured by the Change From Baseline in the Sheehan Disability Scale (SDS) Total Score
Time Frame: Baseline to Week 12
|
A 3-item, self-administered scale that measures the extent a patient is impaired by their disease.
Higher scores indicate more severe impairment.
The SDS total score is calculated as the sum of the score for the 3 intercorrelated domains (school/work, social life, and family life/home responsibilities), ranges from 0 (no impairment) to 30 (most severe impairment).
|
Baseline to Week 12
|
|
Change in Severity of Depressive Symptoms as Measured by Change From Baseline in the Clinical Global Impression-Severity (CGI-S) Score
Time Frame: Baseline to Week 12
|
Clinical Global Impression - Severity (CGI-S) scale rates the severity of the patient's illness at the time of assessment, range from 1 (normal, not ill) to 7 (very severely ill).
|
Baseline to Week 12
|
|
Change in Severity of Depressive Symptoms as Measured by the CGI-I Response (Defined as CGI-I Rating of "Very Much Improved" or "Much Improved") at Week 6
Time Frame: Baseline to Week 6
|
A 3-part, clinician-administered scale that rates the improvement or worsening of the patient's illness from randomization (baseline).
Each item is scored on a 1 to 7 scale.
CGI-I scores >4 indicate worsening, while scores <4 indicate improvement.
|
Baseline to Week 6
|
|
Change in Severity of Depressive Symptoms as Measured by the CGI-I Response (Defined as CGI-I Rating of "Very Much Improved" or "Much Improved") at Week 12
Time Frame: Baseline to Week 12
|
A 3-part, clinician-administered scale that rates the improvement or worsening of the patient's illness from randomization (baseline).
Each item is scored on a 1 to 7 scale.
CGI-I scores >4 indicate worsening, while scores <4 indicate improvement.
|
Baseline to Week 12
|
|
Change From Baseline in Self-rated Severity of Depressive Symptoms as Measured by Quick Inventory of Depressive Symptomatology Self-Rated 16-item Scale (QIDS-SR-16) Total Score
Time Frame: Baseline to Week 12
|
A 16-question self-report inventory that includes the 9 Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria symptom domains: sad mood, concentration, self-outlook, suicidal ideation, involvement, energy/fatigability, sleep disturbance (4 items: initial, middle, late insomnia, and hypersomnia), appetite/weight increased or decrease (4 items), and psychomotor agitation/retardation (2 items).
The QIDS-SR-16 total scores range from 0 (least severe) to 27 (most severe).
|
Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Dhaval A Desai, MD, 1800 Concord Pike, Wilmington, DE 19850
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D6702C00031
- EudraCT number 2011-004690-87
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.